{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:25Z","timestamp":1792978405667,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is used to prevent febrile neutropenia (FN) in breast cancer patients undergoing chemotherapy. However, a small subset of patients still develops FN. This study aimed to assess the real-world incidence of FN and identify potential risk factors in this specific population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included breast cancer patients who received pegfilgrastim prophylaxis at Tokyo Medical University Hospital between February 2019 and December 2024. Inclusion required pegfilgrastim use at least once during chemotherapy. FN was defined as an absolute neutrophil count below 500\/\u00b5L (or a predicted ANC below 1,000\/\u00b5L) and an axillary temperature 37.5\u00a0\u00b0C or higher. Cases of FN and associated risk factors were analyzed using logistic regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 378 patients (median age 53). Tumor subtypes were luminal (50.0%), HER2-positive (20.9%), and triple-negative (29.1%), with dose-dense regimens being the most common (55.8%). Of 2,784 total chemotherapy administrations, pegfilgrastim was used in 2,125 cycles (76.3%). The incidence of FN despite pegfilgrastim was 2.1% (8\/378), with the highest rate observed in immune checkpoint inhibitor-containing regimens (9.1%, 2\/22). Multivariate analysis identified a low baseline platelet count as a significant independent risk factor for combined FN and grade 3\u20134 neutropenia (OR: 0.98; 95% CI: 0.96\u20130.99;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although pegfilgrastim is effective, FN still occurs in a small percentage of patients. A low baseline platelet count was associated with an increased risk of FN or severe neutropenia despite pegfilgrastim prophylaxis, though this finding requires confirmation in larger studies given the limited number of events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01907-7","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:16:08Z","timestamp":1786716968000},"page":"1305-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of febrile neutropenia in breast cancer chemotherapy despite the prophylactic use of pegfilgrastim: a retrospective analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-7989","authenticated-orcid":false,"given":"Hiroki","family":"Kusama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kitaoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujina","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Mizuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2194-1518","authenticated-orcid":false,"given":"Kyoko","family":"Orimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4533","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1907_CR1","doi-asserted-by":"publisher","first-page":"13241","DOI":"10.1038\/s41598-020-70187-8","volume":"10","author":"W Qi","year":"2020","unstructured":"Qi W, Wang X, Gan L, Li Y, Li H, Cheng Q. The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. Sci Rep. 2020;10:13241.","journal-title":"Sci Rep"},{"key":"1907_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.","journal-title":"BMC Cancer"},{"key":"1907_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/009127009203200602","volume":"32","author":"JM Rowe","year":"1992","unstructured":"Rowe JM, Rapoport AP. Hemopoietic growth factors: a review. J Clin Pharmacol. 1992;32:486\u2013501.","journal-title":"J Clin Pharmacol"},{"key":"1907_CR4","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178\u201384.","journal-title":"J Clin Oncol"},{"key":"1907_CR5","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1200\/jco.2013.31.15_suppl.3575","volume":"31","author":"T Pinter","year":"2013","unstructured":"Pinter T, Abella E, Cesas A, Croitoru A, Decaestecker J, Gibbs P, et al. Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). J Clin Oncol. 2013;31:3575.","journal-title":"J Clin Oncol"},{"key":"1907_CR6","unstructured":"Japan Society of Clinical Oncology. G-CSF Appropriate Use Guidelines. 2nd ed. Kanehara & Co., Ltd; 2022. pp. viii\u2013199."},{"key":"1907_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al. NCCN Guidelines(R) Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022;20:436\u201342.","journal-title":"J Natl Compr Canc Netw"},{"key":"1907_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"1907_CR9","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433\u201353.","journal-title":"Eur J Cancer"},{"key":"1907_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2016;24:2309\u201316.","journal-title":"Support Care Cancer"},{"key":"1907_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ajco.13152","volume":"15","author":"M Lee","year":"2019","unstructured":"Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE, et al. Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim. Asia Pac J Clin Oncol. 2019;15:231\u20137.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1907_CR12","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155\u201368.","journal-title":"Mod Pathol"},{"key":"1907_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138:241\u201356.","journal-title":"Arch Pathol Lab Med"},{"issue":"Suppl 1","key":"1907_CR14","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49\u201352.","journal-title":"Clin Infect Dis"},{"key":"1907_CR15","doi-asserted-by":"publisher","first-page":"aab2116","DOI":"10.1126\/science.aab2116","volume":"351","author":"F Notta","year":"2016","unstructured":"Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science. 2016;351:aab2116.","journal-title":"Science"},{"key":"1907_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50:295\u2013306.","journal-title":"Clin Pharmacokinet"},{"key":"1907_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/0091270008320318","volume":"48","author":"BB Yang","year":"2008","unstructured":"Yang BB, Kido A, Salfi M, Swan S, Sullivan JT. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J Clin Pharmacol. 2008;48:1025\u201331.","journal-title":"J Clin Pharmacol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01907-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:03:10Z","timestamp":1792976590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01907-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01907-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed with approval by the institutional review board of Tokyo Medical University (T2024-0103). In accordance with national ethical guidelines, written informed consent was not required for this retrospective study. Instead, information regarding the study was disclosed on the hospital website, and patients were given the opportunity to opt out. The need for individual informed consent was waived by the Institutional Review Board. All data were anonymized prior to analysis and used in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}